Compare $ALZN vs $XBIO | Chartloom

Compare

$ALZN vs $XBIO

Alzamend Neuro Inc · Xenetic Biosciences Inc

ALZN

Alzamend Neuro Inc

XBIO

Xenetic Biosciences Inc

Compare $ALZN vs $XBIO

Comparing Alzamend Neuro Inc and Xenetic Biosciences Inc

ALZNAlzamend Neuro Inc

XBIOXenetic Biosciences Inc

ALZNAlzamend Neuro Inc

Market cap

$6M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-29.5%

52W performance

-47.0%

FCF yield

-106.6%

XBIOXenetic Biosciences Inc

Market cap

$5M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

33.3%

YTD performance

-0.9%

52W performance

-79.4%

FCF yield

-47.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALZN

XBIO

Detailed metrics comparison

ALZN

Alzamend Neuro Inc

XBIO

Xenetic Biosciences Inc

Market Cap

ALZN$6M

XBIO$5M

Enterprise Value

ALZN$-1M

XBIO$-2M

Price

ALZN$1.34

XBIO$2.13

P/E Ratio

ALZNN/A

XBION/A

P/S Ratio

ALZN0.00x

XBIO1.50x

EV/Sales

ALZN0.00x

XBIO-0.49x

EV/EBITDA

ALZN0.00x

XBIO0.00x

P/B Ratio

ALZN1.14x

XBIO0.81x

P/FCF Ratio

ALZNN/A

XBION/A

EV/FCF

ALZN0.17x

XBIO0.69x

PEG Ratio

ALZNN/A

XBION/A

Forward P/E (NTM)

ALZNN/A

XBION/A

Forward P/S (NTM)

ALZNN/A

XBION/A

Revenue (TTM)

ALZN$0

XBIO$3M

Revenue Growth (YoY)

ALZNN/A

XBIO33.3%

Forward Rev Growth

ALZN0.0%

XBIO-16.7%

Gross Margin (TTM)

ALZN0.0%

XBIO98.7%

Operating Margin (TTM)

ALZN0.0%

XBIO0.0%

EBITDA Margin (TTM)

ALZN0.0%

XBIO-81.0%

Net Margin (TTM)

ALZN0.0%

XBIO-75.9%

FCF Margin (TTM)

ALZNN/A

XBIO-70.9%

Net Income (TTM)

ALZN$-9M

XBIO$-2M

FCF (TTM)

ALZN$-7M

XBIO$-2M

EPS (TTM)

ALZN-$2.03

XBIO-$1.08

ROE (TTM)

ALZN-27788.0%

XBIO-4062.0%

ROA (TTM)

ALZN-18419.0%

XBIO-3497.0%

ROIC (TTM)

ALZN-27788.0%

XBIO-4062.0%

Cash

ALZN$8M

XBIO$6M

Debt

ALZN$0

XBIO$0

Net Cash/Debt

ALZN$8M

XBIO$6M

Current Ratio (TTM)

ALZN3.01x

XBIO7.43x

Quick Ratio (TTM)

ALZN2.77x

XBIO7.23x

Debt/Equity (TTM)

ALZN0.00x

XBIO0.00x

Debt/Assets (TTM)

ALZN0.0%

XBIO0.0%

Interest Coverage (TTM)

ALZNN/A

XBION/A

Net Debt/EBITDA (TTM)

ALZN0.00x

XBIO0.00x

Beta

ALZN0.43

XBIO2.36

52W Performance

ALZN-47.0%

XBIO-79.4%

YTD Performance

ALZN-29.5%

XBIO-0.9%

% from 52W High

ALZN-50.0%

XBIO-79.2%

% from 52W Low

ALZN59.5%

XBIO13.9%

Asset Turnover (TTM)

ALZN0.00x

XBIO0.46x

FCF Yield (TTM)

ALZN-106.6%

XBIO-47.4%

Earnings Yield (TTM)

ALZN-141.7%

XBIO-50.7%

Dividend Yield (TTM)

ALZNN/A

XBION/A

Rule of 40

ALZN0.0

XBIO-37.6

EV/GP/RG

ALZNN/A

XBION/A

Ticker research

View ALZN research View XBIO research

Metric	ALZN Alzamend Neuro Inc	XBIO Xenetic Biosciences Inc
Market & Valuation
Market Cap	$6M	$5M
Enterprise Value	$-1M	$-2M
Price	$1.34	$2.13
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1.50x
EV/Sales	0.00x	-0.49x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.14x	0.81x
P/FCF Ratio	N/A	N/A
EV/FCF	0.17x	0.69x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$3M
Revenue Growth (YoY)	N/A	33.3%
Forward Rev Growth	0.0%	-16.7%
Profitability
Gross Margin (TTM)	0.0%	98.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-81.0%
Net Margin (TTM)	0.0%	-75.9%
FCF Margin (TTM)	N/A	-70.9%
Net Income (TTM)	$-9M	$-2M
FCF (TTM)	$-7M	$-2M
EPS (TTM)	-$2.03	-$1.08
ROE (TTM)	-27788.0%	-4062.0%
ROA (TTM)	-18419.0%	-3497.0%
ROIC (TTM)	-27788.0%	-4062.0%
Financial Health
Cash	$8M	$6M
Debt	$0	$0
Net Cash/Debt	$8M	$6M
Current Ratio (TTM)	3.01x	7.43x
Quick Ratio (TTM)	2.77x	7.23x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.43	2.36
52W Performance	-47.0%	-79.4%
YTD Performance	-29.5%	-0.9%
% from 52W High	-50.0%	-79.2%
% from 52W Low	59.5%	13.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.46x
FCF Yield (TTM)	-106.6%	-47.4%
Earnings Yield (TTM)	-141.7%	-50.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-37.6
EV/GP/RG	N/A	N/A
Ticker research	View ALZN research	View XBIO research

Valuation

P/S Ratio

ALZN

0.00x

XBIO

1.50x

EV/FCF

ALZN

0.17x

XBIO

0.69x

Growth & revenue

Revenue Growth TTM

XBIO

33.3%

Forward Revenue Growth

ALZN

0.0%

XBIO

-16.7%

Profitability & performance

Gross Margin

XBIO

98.7%

ALZN

0.0%

ROE

XBIO

-4062.0%

ALZN

-27788.0%

FCF Yield %

XBIO

-47.4%

ALZN

-106.6%

52-Week Performance

ALZN

-47.0%

XBIO

-79.4%

Detailed metrics comparison

ALZN

Alzamend Neuro Inc

XBIO

Xenetic Biosciences Inc

Market Cap

ALZN$6M

XBIO$5M

Enterprise Value

ALZN$-1M

XBIO$-2M

Price

ALZN$1.34

XBIO$2.13

P/E Ratio

ALZNN/A

XBION/A

P/S Ratio

ALZN0.00x

XBIO1.50x

EV/Sales

ALZN0.00x

XBIO-0.49x

EV/EBITDA

ALZN0.00x

XBIO0.00x

P/B Ratio

ALZN1.14x

XBIO0.81x

P/FCF Ratio

ALZNN/A

XBION/A

EV/FCF

ALZN0.17x

XBIO0.69x

PEG Ratio

ALZNN/A

XBION/A

Forward P/E (NTM)

ALZNN/A

XBION/A

Forward P/S (NTM)

ALZNN/A

XBION/A

Revenue (TTM)

ALZN$0

XBIO$3M

Revenue Growth (YoY)

ALZNN/A

XBIO33.3%

Forward Rev Growth

ALZN0.0%

XBIO-16.7%

Gross Margin (TTM)

ALZN0.0%

XBIO98.7%

Operating Margin (TTM)

ALZN0.0%

XBIO0.0%

EBITDA Margin (TTM)

ALZN0.0%

XBIO-81.0%

Net Margin (TTM)

ALZN0.0%

XBIO-75.9%

FCF Margin (TTM)

ALZNN/A

XBIO-70.9%

Net Income (TTM)

ALZN$-9M

XBIO$-2M

FCF (TTM)

ALZN$-7M

XBIO$-2M

EPS (TTM)

ALZN-$2.03

XBIO-$1.08

ROE (TTM)

ALZN-27788.0%

XBIO-4062.0%

ROA (TTM)

ALZN-18419.0%

XBIO-3497.0%

ROIC (TTM)

ALZN-27788.0%

XBIO-4062.0%

Cash

ALZN$8M

XBIO$6M

Debt

ALZN$0

XBIO$0

Net Cash/Debt

ALZN$8M

XBIO$6M

Current Ratio (TTM)

ALZN3.01x

XBIO7.43x

Quick Ratio (TTM)

ALZN2.77x

XBIO7.23x

Debt/Equity (TTM)

ALZN0.00x

XBIO0.00x

Debt/Assets (TTM)

ALZN0.0%

XBIO0.0%

Interest Coverage (TTM)

ALZNN/A

XBION/A

Net Debt/EBITDA (TTM)

ALZN0.00x

XBIO0.00x

Beta

ALZN0.43

XBIO2.36

52W Performance

ALZN-47.0%

XBIO-79.4%

YTD Performance

ALZN-29.5%

XBIO-0.9%

% from 52W High

ALZN-50.0%

XBIO-79.2%

% from 52W Low

ALZN59.5%

XBIO13.9%

Asset Turnover (TTM)

ALZN0.00x

XBIO0.46x

FCF Yield (TTM)

ALZN-106.6%

XBIO-47.4%

Earnings Yield (TTM)

ALZN-141.7%

XBIO-50.7%

Dividend Yield (TTM)

ALZNN/A

XBION/A

Rule of 40

ALZN0.0

XBIO-37.6

EV/GP/RG

ALZNN/A

XBION/A

Ticker research

View ALZN research View XBIO research

Metric	ALZN Alzamend Neuro Inc	XBIO Xenetic Biosciences Inc
Market & Valuation
Market Cap	$6M	$5M
Enterprise Value	$-1M	$-2M
Price	$1.34	$2.13
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1.50x
EV/Sales	0.00x	-0.49x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.14x	0.81x
P/FCF Ratio	N/A	N/A
EV/FCF	0.17x	0.69x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$3M
Revenue Growth (YoY)	N/A	33.3%
Forward Rev Growth	0.0%	-16.7%
Profitability
Gross Margin (TTM)	0.0%	98.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-81.0%
Net Margin (TTM)	0.0%	-75.9%
FCF Margin (TTM)	N/A	-70.9%
Net Income (TTM)	$-9M	$-2M
FCF (TTM)	$-7M	$-2M
EPS (TTM)	-$2.03	-$1.08
ROE (TTM)	-27788.0%	-4062.0%
ROA (TTM)	-18419.0%	-3497.0%
ROIC (TTM)	-27788.0%	-4062.0%
Financial Health
Cash	$8M	$6M
Debt	$0	$0
Net Cash/Debt	$8M	$6M
Current Ratio (TTM)	3.01x	7.43x
Quick Ratio (TTM)	2.77x	7.23x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.43	2.36
52W Performance	-47.0%	-79.4%
YTD Performance	-29.5%	-0.9%
% from 52W High	-50.0%	-79.2%
% from 52W Low	59.5%	13.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.46x
FCF Yield (TTM)	-106.6%	-47.4%
Earnings Yield (TTM)	-141.7%	-50.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-37.6
EV/GP/RG	N/A	N/A
Ticker research	View ALZN research	View XBIO research